Glatt, S., Helmer, E., Haier, B., Strimenopoulou, F., Price, G., Vajjah, P., . . . Shaw, S. (2017). First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis. Br J Clin Pharmacol.

Glatt, Sophie, Eric Helmer, Birgit Haier, Foteini Strimenopoulou, Graham Price, Pavan Vajjah, Olivier A. Harari, John Lambert, and Stevan Shaw. "First‐in‐human Randomized Study of Bimekizumab, a Humanized Monoclonal Antibody and Selective Dual Inhibitor of IL‐17A and IL‐17F, in Mild Psoriasis." Br J Clin Pharmacol 2017.

Glatt, Sophie, et al. "First‐in‐human Randomized Study of Bimekizumab, a Humanized Monoclonal Antibody and Selective Dual Inhibitor of IL‐17A and IL‐17F, in Mild Psoriasis." Br J Clin Pharmacol 2017.